BrightGene: BGM1812 injection has received FDA approval for clinical trials in the United States
I'm LongbridgeAI, I can summarize articles.BrightGene announced that it has received approval from the U.S. FDA to conduct Phase I clinical trials for BGM1812 injection, aimed at treating overweight or obesity. This injection is a novel long-acting Amylin analog with good molecular activity and pharmaceutical stability, capable of suppressing appetite by activating the brain's satiety pathways, delaying gastric emptying, and inhibiting glucagon secretion, possessing multiple weight loss mechanisms
According to the Zhitong Finance APP, BrightGene (688166.SH) announced that the company has received approval from the U.S. FDA (i.e., the U.S. Food and Drug Administration) to conduct Phase I clinical trials of BGM1812 injection for the treatment of overweight or obesity.
BGM1812 injection is a newly designed long-acting Amylin analog optimized by the company, with good molecular activity and pharmaceutical stability. Amylin, as a satiety peptide hormone composed of 37 amino acids, is co-released into the bloodstream by pancreatic β cells along with insulin. It suppresses appetite by activating the brain's satiety pathways while delaying gastric emptying and inhibiting glucagon secretion, thus having multiple weight loss mechanisms